July 25, 2017 — ViewRay Inc. announced recently that the first cancer patients have been treated using the company's MRIdian Linac system at Henry Ford Health System in Metro Detroit. MRIdian Linac is the world's only U.S. Food and Drug Administration (FDA)-cleared magnetic resonance imaging (MRI)-guided radiation therapy system with linear accelerator-based delivery. MRIdian Linac is the company's second-generation system.
"MRIdian offers us the ability to finally see where the patient's tumor is located in real time using MRI imaging so we know what changes are taking place inside the body and can make the necessary adjustments in real time," said Benjamin Movsas, M.D., chair of radiation oncology at the Henry Ford Cancer Institute, part of Henry Ford Health System. "This precision radiation enables us to target our therapy to each and every patient individually. I believe this is going to change how we use radiation to treat cancer."
Of particular interest to the clinicians at Henry Ford Health System are the MRIdian Linac system's on-table adaptive capabilities, which include the ability to reshape the radiation to match changes in the patient's anatomy between treatments.
Read an article from the July 2017 issue of ITN on MRI-guided radiation therapy.
For more information: www.viewray.com
February 13, 2026 
